Details

Analysis File of Drug-Induced Lung Injury

Expert Opinion for Analysis of Big Data

von: Akihiko Gemma
CHF 118.00
Verlag:	Springer
Format:	PDF
Veröffentl.:	01.08.2024
ISBN/EAN:	9789819734467
Sprache:	englisch

In den Warenkorb

Als Gutschein

Dieses eBook enthält ein Wasserzeichen.

Beschreibungen

Titelbeschreibung

This book describes the pathologic conditions of drug-induced lung injuries, monitoring strategies, and guides on how to interpret the evidence. It also dives into particular drugs that caused the disorder, such as EGFR inhibitors, anti-EGFR antibodies, mTOR inhibitors, proteasome inhibitors, immune checkpoint inhibitors, neoangiogenesis inhibitors, and other molecular targeted drugs. It outlines the analysis and interpretation of the post-marketing survey on surveillance of each drug for inducing pulmonary lesions presenting diffuse haziness. The data and analysis from this survey are valuable since a guideline is yet to be established due to limited clinical evidence and cases. As new drugs are developed, establishing treatment and event management is crucial. Thus, <em>Drug-induced Pulmonary Disorder in Medical Oncology - Expert Opinion to Decipher Big Data </em>summarizes the accumulated information to provide a foundation for further research advancement. The book<em> </em>offers a refreshing alternative to current approaches to medical oncology and respiratory diseases professionals and will also attract medical affairs members in global pharmaceutical companies.<p></p>

<p> </p>

Inhaltsverzeichnis

<p>Part I Understanding Drug-Induced Lung Injuries.- 1 Understanding Drug-Induced Lung Injuries.- Part 2 Actual Practice in Drug-Induced Lung Injuries of Each Drug.- 2 EGFR inhibitors (gefitinib, erlotinib, afatinib, osimertinib).- 3 Anti-EGFR antibodies (cetuximab, panitumumab, necitumumab).- 4 mTOR inhibitors (temsirolimus, everolimus).- 5 Proteasome inhibitor (bortezomib).- 6 Immune checkpoint inhibitors (nivolumab, pembrolizumab, atezolizumab, durvalumab).- 7 Neoangiogenesis inhibitors (sunitinib, sorafenib, bevacizumab).- 8 Other molecular targeted drugs (crizotinib, alectinib, etc.).- 9 Antibody-drug conjugates (ADC) (trastuzumab emtansine, trastuzumab deruxtecan).- 10 Anti-cancer drugs (TS-1, taxanes, CPT-11, platinum-containing drugs, etc.).</p>

Autorenportrait

<div>Akihiko Gemma</div><div>President, Nippon Medical School</div><div><br></div><div><div>1983: Graduated from the Faculty of Medicine of Nippon Medical School</div><div>1986: Served as a trainee doctor in the Pathology Department of the National Cancer Center Research Institute</div><div>1989: Graduated from Nippon Medical School Graduate School</div><div>1995: Studied at National Cancer Institute of National Institutes of Health (NIH), the United States</div><div>1998: Appointed as a lecturer to Nippon Medical School</div><div>2004: Appointed as an associate professor</div><div>2008: Appointed as a senior professor to the Department of Medicine (Respiratory, Infectious Disease and Oncology Division)</div><div>2012: Appointed as a professor to the Graduate School of Medicine in charge of respiratory medicine</div><div>2013: Appointed dean of Department of Medicine</div><div>2015： Appointed president</div></div>

Back cover copy

<p>This book describes the pathologic conditions of drug-induced lung injuries, monitoring strategies, and guides on how to interpret the evidence. It also dives into particular drugs that caused the disorder, such as EGFR inhibitors, anti-EGFR antibodies, mTOR inhibitors, proteasome inhibitors, immune checkpoint inhibitors, neoangiogenesis inhibitors, and other molecular targeted drugs. It outlines the analysis and interpretation of the post-marketing survey on surveillance of each drug for inducing pulmonary lesions presenting diffuse haziness. The data and analysis from this survey are valuable since a guideline is yet to be established due to limited clinical evidence and cases. As new drugs are developed, establishing treatment and event management is crucial. Thus, <em>Drug-induced Pulmonary Disorder in Medical Oncology - Expert Opinion to Decipher Big Data </em>summarizes the accumulated information to provide a foundation for further research advancement. The book<em> </em>offers a refreshing alternative to current approaches to medical oncology and respiratory diseases professionals and will also attract medical affairs members in global pharmaceutical companies.</p>

Sonderbeitrag

Presents abundant knowledge on event management of drug-induced lung disorders In-depth analysis and interpretation of post-marketing surveillance data for various drugs causing pulmonary disorders Unique focus on bridging clinical evidence gaps, offering a foundation for advanced research in medical oncology